Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus

Cancer Research

Volumn 67, Issue 20, 2007, Pages 10038-10046

  Zhang, Qian ^a   Yu, Yong A ^a   Wang, Ena ^b   Chen, Nanhai ^a   Danner, Robert L ^c   Munson, Peter J ^d   Marincola, Francesco M ^b   Szalay, Aladar A ^a,e  

^a GENELUX CORPORATION   (United States)

^b Immunogenetics Laboratory   (Czech Republic)

^c Clinical Center   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCURONIDASE; CHEMOKINE; CYTOKINE; GREEN FLUORESCENT PROTEIN; HEMAGGLUTININ; HYBRID PROTEIN; INTERFERON REGULATORY FACTOR 1; ONCOLYTIC HERPES VIRUS; RENILLA LUCIFERIN 2 MONOOXYGENASE; STAT1 PROTEIN; THYMIDINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST TUMOR; CANCER INHIBITION; CONTROLLED STUDY; DNA FINGERPRINTING; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG SAFETY; FEMALE; GENE CASSETTE; GENE EXPRESSION; GENE LOCUS; GENETIC CODE; GENETIC TRANSCRIPTION; HUMAN; IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR REGRESSION; VIRUS GENE; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; BETA-GALACTOSIDASE; BREAST NEOPLASMS; CERCOPITHECUS AETHIOPS; FEMALE; FIBROBLASTS; GLUCURONIDASE; GREEN FLUORESCENT PROTEINS; HUMANS; LUCIFERASES, RENILLA; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; RECOMBINANT FUSION PROTEINS; THYMIDINE KINASE; TRANSCRIPTION, GENETIC; VACCINIA VIRUS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 35448962430     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0146     Document Type: Article

References (37)

1. Coffin J, Varmus H, Hughes S, editors. Retroviruses. Cold Spring Harbor (NY): Cold Spring Harbor Press; 2000.
2. Talbot SJ, Crawford DH. Viruses and tumours-an update. Eur J Cancer 2004;40:1998-2005.
3. Heise CC, Williams AM, Xue S, Propst M, Kirn DH. intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res 1999;59:2623-8.
4. Grote D, Russell SJ, Cornu TI, et al. Live attenuated measles virus induces regression of human lymphoma xenographs in immunodeficient mice. Blood 2001;97: 3746-54.
5. Stojdl DF, Lichty BD, tenOever BR, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anticancer agents. Cancer Cell 2003;4:263-75.
6. Phuangsab A, Lorence RM, Reichard KW, Peeples ME, Walter RJ. Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. Cancer Lett 2001;172:27-36.
7. Pecora AL, Rizvi N, Cohen GI, et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 2002;20:2251-66.
8. Norman KL, Coffey MC, Hirasawa K, et al. Reovirus oncolysis of human breast cancer. Hum Gene Ther 2002; 13:641-52.
9. Hirasawa K, Nishikawa SG, Norman KL, et al. Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 2003;63:348-53.
10. De Palma M, Venneri MA, Naldini L. In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors. Hum Gene Ther 2003;14:1193-206.
11. Fu X, Zhang X. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype. Cancer Res 2002;62:2306-12.
12. Nakamori M, Fu X, Pettaway CA, Zhang X. Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancer. Prostate 2004;60:53-60.
13. Shafren DR, Au GG, Nguyen T, et al. Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21. Clin Cancer Res 2004;10:53-60.
14. Tseng JC, Levin B, Hurtado A, et al. Systemic tumor targeting and killing by Sindbis viral vectors. Nat Biotechnol 2004;22:70-7.
15. Vaha-Koskela MJV, Kallio JP, Jansson LC, et al. Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice. Cancer Res 2006;66: 7185-94.
16. Agrawal N, Bettegowda C, Cheong I, et al. Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci U S A 2004;101:15172-7.
17. Zhao M, Yang M, Li XM, et al. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci U S A 2005;102:755-60.
18. Puhlmann M, Brown CK, Gnant M, et al. Vaccinia as a vector for tumor-directed gene therapy: Biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther 2000;7:66-73.
19. McCart JA, Ward JM, Lee J, et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 2001;61:8751-7.
20. Shida H, Hinuma Y, Hatanaka M, et al. Effects and virulences of recombinant vaccinia viruses derived from attenuated strains that express the human T-cell leukemia virus type I envelope gene. J Virol 1988;62:4474-80.
21. Lattime EC, Lee SS, Eisenlohr LC, Mastrangelo MM. In situ cytokine gene transfection using vaccinia virus vectors. Semin Oncol 1996;23:88-100.
22. Timiryasova TM, Chen B, Haghighat P, Fodor I. Vaccinia virus-mediated expression of wild-type p53 suppresses glioma cell growth and induces apoptosis. Int J Oncol 1999;14:845-54.
23. Kwak H, Horig H, Kaufman HL. Poxviruses as vectors for cancer immunotherapy. Curr Opin Drug Discov Devel 2003;6:161-8.
24. Yu YA, Shabahang S, Timiryasova TM, et al. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol 2004;22:313-20.
25. 111In-pentetreotide. Mol Ther 2004;10:553-61.
26. Rathinavelu P, Malave A, Raney SR, Hurst J, Roberson CT, Rathinavelu A. Expression of mdm-2 oncoprotein in the primary and metastatic sites of mammary tumor (GI-101) implanted athymic nude mice. Cancer Biochem Biophys 1999;17:133-46.
27. Timiryasova TM, Yu YA, Shabahang S, Fodor I, Szalay AA. Visualization of vaccinia virus infection using the renilla-luciferase-GFP fusion protein. In: Case JF, Herring PJ, Robison BH, Haddock SHD, Kricka LJ, Stanley PE, editors. Proceeding of the 11th International Symposium on Bioluminescence & Chemiluminescence. River Edge (NJ):World Scientific Publishing Co. pte. Ltd; 2000. p. 457-60.
28. Chakrabarti S, Sisler JR, Moss B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 1997;23:1094-7.
29. Flexner C, Broyles SS, Earl P, Chakrabarti S, Moss B. Characterization of the human immunodeficiency virus gag/pol gene products expressed by recombinant vaccinia viruses. Virology 1988;166:339-49.
30. Joklik WK. The purification of four strains of poxvirus. Virology 1962;18:9-18.
31. Bell JC, Lichty B, Stojdl D. Getting oncolytic virus therapies off the ground. Cancer Cell 2003;4:7-11.
32. Buller RM, Chakrabarti S, Moss B, Fredrickson T. Cell proliferative response to vaccinia virus is mediated by VGF. Virology 1988;164:182-92.
33. Silobrcic V, Zietman AL, Ramsay JR, Suit HD, Sedlacek RS. Residual immunity of athymic NCr/Sed nude mice and the xenotransplantation of human tumors. Int J Cancer 1990;45:325-33.
34. Mantovani A, Romero P, Palucka KA, Marincola FM. Tumor immunity: effector response to tumor and the influence of the microenvironment. The Lancet. In press.
35. Hicks AM, Riedlinger G, Willingham MC, et al. Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proc Natl Acad Sci U S A 2006;103:7753-8.
36. Zhu J, Martinez J, Huang X, Yang Y. Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-β. Blood 2007;109: 619-25.
37. Ross DT, Scherf U, Eisen MB, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000;24:227-35.